Connor Clark & Lunn Investment Management Ltd. Trims Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 19.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,351 shares of the company’s stock after selling 11,704 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Aura Biosciences were worth $422,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Levin Capital Strategies L.P. increased its position in Aura Biosciences by 194.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. American International Group Inc. grew its holdings in shares of Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares in the last quarter. Long Focus Capital Management LLC grew its holdings in shares of Aura Biosciences by 113.4% during the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after buying an additional 561,766 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Aura Biosciences in the first quarter valued at approximately $144,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Analyst Upgrades and Downgrades

AURA has been the subject of several recent analyst reports. JMP Securities lifted their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. BTIG Research lifted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Scotiabank lifted their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Finally, Cowen reiterated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $23.00.

Insider Transactions at Aura Biosciences

In related news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 5.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Los Pinos Elisabet De sold 9,200 shares of the company’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the transaction, the insider now directly owns 320,647 shares of the company’s stock, valued at approximately $3,443,748.78. The trade was a 2.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 79,081 shares of company stock valued at $891,353 over the last quarter. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $9.31 on Friday. The stock has a 50-day simple moving average of $9.73 and a 200-day simple moving average of $8.63. The stock has a market capitalization of $465.03 million, a P/E ratio of -5.38 and a beta of 0.33. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. Analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.